Bend Research, Inc.

Cymabay Therapeutics, Inc.

Sweetwater Solutions, LLC

Bend Reseach, Inc.

Pfizer Products Inc.

Rodney James Ketner

Dwayne Thomas Friesen

Ravi Mysore Shanker

James William West

Douglas Alan Lorenz

James A S Nightingale

David Keith Lyon

Walter Christian Babcock

William John Curatolo

Charles A McWherter

Marshall David Crew

David Brian Karpf

Brian K Roberts

Julian B Lo

Robert Louis Martin

James Mathew Mullin

Daniel Elmont Dobry

Bruno Caspar Hancock

Michael Jon Gumkowski

James Blair West

Michael Edward Grass

James Alan Shriver Nightingale

Charles A Mcwherter

James Matthew Mullin

Ravi Moysore Shanker

Jennifer Hsing-Chung Chu

Timothy Joseph Mc Dermott

Oral rehydration solutions (ORSs), methods of preparing ORSs and methods of delivering rehydration therapy are disclosed herein. In some embodiments, an ORS includes a non-starch viscosity enhancing polymer and a sodium salt. The ORS may include at least approximately 50 millimoles of dissolved sodium per liter. Other embodiments may be described and/or claimed.

Oral rehydration solution with improved taste

This invention relates to the field of pharmaceutical chemistry and, more specifically, to pharmaceutical formulations as well as to intermediates used to prepare such formulations and to methods for manufacturing such formulations.

Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine

In one aspect, pharmaceutical compositions comprising dispersions of an acid-sensitive drug and a neutral dispersion polymer are disclosed. The acid-sensitive drug has improved chemical stability relative to dispersions of the drug and acidic polymers. In another aspect, pharmaceutical compositions of low-solubility drugs and amphiphilic, hydroxy-functional vinyl copolymers are disclosed.

Pharmaceutical compositions of dispersions of drug and neutral polymers

A secondary drying process is disclosed for removing residual solvent from drug-containing particles that have been formed by solvent-based processes.

Drying of drug-containing particles

A solid amorphous dispersion comprises a cholesteryl ester transfer protein (CETP) inhibitor, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase inhibitor), and a concentration enhancing polymer. At least a major portion of the CETP inhibitor in the dispersion is amorphous. The solid amorphous dispersion provides concentration-enhancement of the CETP inhibitor when administered to an aqueous use environment.

Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase

A pharmaceutical composition comprises a dispersion comprising a low-solubility drug and a matrix combined with a concentration-enhancing polymer. At least a major portion of the drug is amorphous in the dispersion. The compositions improve the stability of the drug in the dispersion, and/or the concentration of drug in a use environment.

Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers

Pharmaceutical compositions comprising a poorly water soluble ionizable drug, a cationic species and a dispersion polymer are disclosed, together with a process for forming the compositions. The neutral form of the drug has (i) a solubility of less than 1 mg/ml, in aqueous solution at a pH between 6 and 7, (ii) a solubility of less than 20 mg/mL in a volatile organic solvent, and (iii) an acidic pKa value of greater than 5. At least 90 wt % of the drug in the solid dispersion being in a non-crystalline form. The drug, the cationic species, and the dispersion polymer constitute at least 80 wt % of the solid dispersion.

Spray dried formulation

Pharmaceutical compositions comprised of low-solubility and/or acid-sensitive drugs and neutralized acidic polymers are disclosed.

Pharmaceutical compositions of drugs and neutralized acidic polymers

Growing community of inventors

Bend, OR, United States of America

Rodney James Ketner